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Background: The WHO has recently published the FRAXW tool to determine the absolute risk of osteoporotic
fracture at 10 years. This tool has not yet been validated in Spain.
Methods/design: A prospective observational study was undertaken in women in the FRIDEX cohort (Barcelona) not
receiving bone active drugs at baseline. Baseline measurements: known risk factors including those of FRAXW and a DXA.
Follow up data on self-reported incident major fractures (hip, spine, humerus and wrist) and verified against patient
records. The calculation of absolute risk of major fracture and hip fracture was by FRAXW website. This work follows the
guidelines of the STROBE initiative for cohort studies. The discriminative capacity of FRAXW was analyzed by the Area
Under Curve (AUC), Receiver Operating Characteristics (ROC) and the Hosmer-Lemeshow goodness-of-fit test. The
predictive capacity was determined using the ratio of observed fractures/expected fractures by FRAXW (ObsFx/ExpFx).
Results: The study subjects were 770 women from 40 to 90 years of age in the FRIDEX cohort. The mean age
was 56.8 ± 8 years. The fractures were determined by structured telephone questionnaire and subsequent
testing in medical records at 10 years. Sixty-five (8.4%) women presented major fractures (17 hip fractures).
Women with fractures were older, had more previous fractures, more cases of rheumatoid arthritis and also
more osteoporosis on the baseline DXA. The AUC ROC of FRAXW for major fracture without bone mineral
density (BMD) was 0.693 (CI 95%; 0.622-0.763), with T-score of femoral neck (FN) 0.716 (CI 95%; 0.646-0.786),
being 0.888 (CI 95%; 0.824-0.952) and 0.849 (CI 95%; 0.737-0.962), respectively for hip fracture. In the model with
BMD alone was 0.661 (CI 95%; 0.583-0.739) and 0.779 (CI 95%; 0.631-0.929). In the model with age alone was 0.668 (CI 95%;
0.603-0.733) and 0.882 (CI 95%; 0.832-0.936). In both cases there are not significant differences against FRAXWmodel. The
overall predictive value for major fracture by ObsFx/ExpFx ratio was 2.4 and 2.8 for hip fracture without BMD. With BMD
was 2.2 and 2.3 respectively. Sensitivity of the four was always less than 50%. The Hosmer-Lemeshow test showed a good
correlation only after calibration with ObsFx/ExpFx ratio.
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Conclusions: The current version of FRAXW for Spanish women without BMD analzsed by the AUC ROC
demonstrate a poor discriminative capacity to predict major fractures but a good discriminative capacity for hip
fractures. Its predictive capacity does not adjust well because leading to underdiagnosis for both predictions
major and hip fractures. Simple models based only on age or BMD alone similarly predicted that more complex
FRAXW models.Background
The major manifestation or clinical consequence of
osteoporosis is the appearance of osteoporotic fracture
or fragility fracture [1]. It is well known that osteopor-
otic fractures involve a higher incidence of new fractures
and lead to disability [2]. Hip fractures and those of the
vertebrae with clinical manifestations are especially
important since they carry an increase in mortality [3,4].
There is currently wide consensus regarding the need to
develop strategies for the prevention of fractures and in
the last years it has been recommended that the decision
and the threshold of intervention be based on clinical
assessment of risk of fragility fracture [5-8] and not only
on the values of BMD and the relative risk as in the
meta-analysis by Marshall D et al. [9].
Multiple epidemiological studies have described differ-
ent clinical risk factors of osteoporotic fracture (CRFs)
and which are been associated with an increased risk of
developing osteoporosis and/or fragility fractures. None-
theless, not all have determined a strong association,
and the presence of these CRFs has not been uniform in
the different studies and systematic reviews [10-14].
Most of the most powerful CRFs are concordant in
different populations and, in general, similar for different
fractures. Fractures related to falls have additional risk
factors such as the number of falls, scarce physical activ-
ity and others such as the use of a walking stick, the
need for help to get up from a chair, etc.). The CRFs
associated with lifestyle such as smoking, alcohol intake
or caffeine, low calcium consumption and scarce phys-
ical exercise have shown greater variability and lesser
uniformity among the different studies [6,7]. Finally, the
influence of some risk factors on the risk of fragility frac-
ture has been demonstrated in different meta-analyses
and systematic reviews [15-20]. As previously commen-
ted, since more than 15 years ago there has been
evidence that BMD below the standard values is one of
the important risk factors for fragility fracture [21,22].
More recently, however, other CRFs with as great or
greater specific weight in the determination of risk of
fragility fracture have been reported [11-13,22].
It is well known that there is an important variation in
the relative risk of hip fracture in both men and women
at an international level. The WHO itself has performed
numerous investigations on this difference. In one of thelatest studies this difference was defined as a standar-
dised rate at 10 years, being, in the most extreme cases,
15-fold greater between countries such as Norway and
Chile [23].
The studies performed by the Bone and Mineral
Research Program, in Garvan Institute of Medical
Research show that the combination of BMD and non-
invasive clinical risk factors in a nomogram could be
useful for identifying high-risk individuals for interven-
tion to reduce the risk of hip fracture [24]. With the
objective to make a purpose of when were the better
moment and the patient who better benefits of new
drugs available for the prevention of osteoporotic, World
Health Organization Collaborating Centre for Metabolic
Bone Diseases, University of Sheffield, UK developed the
FRAX tool. Both are useful tools to estimate absolute
risk of fracture for clinical practice but both have limita-
tions: They discriminative ability was only moderate in
older women (mean 74 years old) which may limit their
clinical utility [25].
Both Garvan and FRAX are widely available tools:
http://www.garvan.org.au/bone-fracture-risk/ and http://
www.shef.ac.uk/FRAX/ but both models still need to be
validated in different populations before they can be
generalized to other populations and further studies will
be needed to validate their contribution in selecting
patients who will achieve fracture risk reduction with
anti-osteoporosis therapy. With the current available
algorithms, a possible clinical application may be to use
FRAX as the primary model and to consider using
Garvan in patients with recurrent fractures and falls [25].
Since the technical reports of 1994 [26] and their
review in 2001 few changes have been made with respect
to the WHO recommendations on the management of
osteoporosis. In 2007, the WHO published a new tool
for the evaluation of absolute risk of fragility fracture:
the FRAX tool [27-30]. This tool was developed by
WHO to evaluate fragility fracture risk for a 10 year
period in patients for many countries [31-33].
The extension of a method for calculating the risk
(probability) of fractures using the FRAX tool is foresee-
able in Spain similar to what is occurring in other coun-
tries since its publication [34,35]. But before its clinical
use its necessary to validate the calculator in a local co-
hort [29,30].
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The objective of this study was to evaluate the discrim-
inative and predictive capacity of the FRAX tool to
determine osteoporotic or fragility fracture in Spain at
10 years.
This study describes the discriminatory capacity
using the AUC-ROC of the FRAX tool to determine
which Spanish women will have an osteoporotic frac-
ture over the 10 years following the determination of
the risk. On the other hand, the global predictive cap-
acity of the FRAX tool has been calculated to detect
the osteoporotic fractures on comparing the fractures
observed over the 10 years with those expected by the
FRAX tool.Methods
Methods/design
The protocol, procedures and main characteristics of the
study have recently been published [35].
Briefly, the FRIDEX cohort (Fracture RIsk factors
and bone DEnsitometry type central dual X-ray) is
constituted of men and women referred by general
practitioners and specialists for undergoing central
bone densitometry by Dual-energy X-ray absorpti-
ometry (DXA) for the initial study of osteoporosis or
treatment follow up, who accept to answer an exten-
sive questionnaire on risk factors (QRF) for osteopor-
otic fracture (family history of osteoporosis and hip
fracture, clinical risk factors and lifestyle habits related
to diet and toxic substances) [35]. This cohort was
started in 1999 at the Bone Densitometry Unit of the
Department of Nuclear Medicine of the University
Hospital Vall d’Hebrón, Barcelona, Spain.
During the baseline visit at the reference centre
informed consent to participate was requested and a
QRF for osteoporotic fractures is given during the
visit and anthropometric parameters are determined.
Ten years after the first QRF and DXA the patients
were asked to answer a phone survey to know the
evolution of the study variables and outcomes such as
new personal or parental fractures, new disease or
prescriptions.Study population and enrolment procedures
This multicentre study was carried out by family prac-
titioners and other specialists who refer patients to the
same reference centre for undertaking BMD. The cri-
teria for referral followed the recommendations of the
WHO of not performing a population screening but to
select cases among those at greatest risk of having
osteoporosis and subsequent osteoporotic fractures or
the follow up and control of patients already receiving
specific treatment.Participants reside mostly in urban areas and were
referred for DXA scan by family doctors, ambulatory
specialists and hospital specialists.
Randomised sample (simple computerised randomisation
stratified by sex) was obtained of women from 40 to 90
years of age in the FRIDEX cohort for 10 years since the
baseline DXA and QRF.
Eligibility criteria
Patient inclusion criteria
The study subjects were Caucasian women, ≥ 40 and ≤
90 years of age at the time of inclusion in the FRIDEX
cohort [35], understood and spoke the Spanish language,
were able to respond to the initial questionnaire done at
the surgery and a ten-year follow up structured tele-
phone questionnaire (TQ). All accepted to participate in
the study providing the corresponding verbal consent.
Physically or psychically handicapped patients were
included if the relatives or care providers accepted to
answer the TQ.
Patient exclusion criteria
Subjects < 40 or > 90 years of age at the time of the first
DXA and QRF were excluded since the FRAX tool does
not allow the calculation of the adjusted risk outside this
age range. Patients with physical or psychological limita-
tions impeding their participation and whose relatives
did not accept to respond to the TQ were excluded as
were those with Paget’s disease, cancer with bone
involvement or disease which may simulate osteoporosis
(i.e. myeloma). Patients from ethnic groups other than
Caucasian were not included since other studies have
demonstrated different risk characteristics. Patients not
providing consent to the TQ and those without a tele-
phone to contact or did not respond after 3 calls made
at different times according to the procedure manual
were also excluded from the study. Dead patients were
not studied because of the impossibility of obtain all the
study variables or to answer the questionnaire by
relatives.
Data collection
The sample ordering was performed using randomised
numbers for each month and the calls were made in this
order. The baseline variables of QRF and BMD were col-
lected from January to July 2000. The follow up variables
were collected at the same month during 2010 by TQ to
complete the 10 years of follow up. The TQ was col-
lected regarding the fragility fractures occurring from
the time of inclusion until the date of the TQ as well as
other information on known factors of fracture risk and
falls. In all cases of fracture the medical records of the
patients were reviewed and, when necessary, we
requested a medical report for its validation. All cases of
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a motor vehicle accident or major trauma were excluded
from analysis. Dead patients were not studied because of
the impossibility of obtain all the study variables and to
answer the questionnaire by relatives.
Baseline variables
Height, weight, body mass index were obtained during
baseline DXA scan. The rest of baseline items were
obtained by semi structured questionnaire by interviewer
during the same visit. On the other hand, the variables
are set according to the instructions of the official
website of FRAX [http://www.shef.ac.uk/FRAX/tool.jsp?
lang=sp]. The variables which are mentioned in the
questionnaire were defined as well according to standard
units of measurement for each. Regarding the risk of
alcohol consumption, the quantification of consumption
in standard drinks (UBEs) allows rapid quantification of
consumption and its easy conversion into grams of pure
alcohol. The value of the UBE in Spain with a slight
North–south gap is set to 10 g of alcohol and is equiva-
lent to a consumption of wine (100ml), sparkling wine
(100 ml) or beer (200 ml) half and consumption of dis-
tilled or combined (25 ml). Weekly risky drinking for
women and over 65 years is that is> 17 UBEs and men>
28-UBEs. The phone records of alcohol consumption
have shown good validity and correlation in Mediterranean
countries where alcohol consumption is widespread. Only
in case of personal circumstances (deafness, slurred speech,
etc.) a part of the information was obtained through regular
cohabiting relatives of patients in 15 of 770 cases (1.9%).
BMD measurement was determined by central DXA
according to the 2007 recommendations of the Inter-
national Society for Clinical Densitometry (ISCD) (available
at: www.iscd.org/Visitors/positions/OfficialPositionsText.
cfm) for the interpretation of the results using a Lunar
GE model Prodigy Advance densitometer with 11.4
software and with BMD and T-score determination with
NHANES III references. The densitometry diagnostic
criteria used were the 1994 WHO criteria which classify
the results into 3 groups according to the levels of BMD
values of the femoral neck: normal (T-score >−1), osteo-
penia (T-score between −2.4 and −1 inclusive) and osteo-
porosis (T-score ≤ −2.5).
The estimated absolute risk of fracture during the 10-year
period according to the FRAX tool was determined
through the official website (version 3.2 accessed on
October 2010). The calculations of the probability of
fracture with or without the T-score of femoral neck and
lumbar spine (L1-L4) were analysed in parallel by two blind
investigators (patient entities were kept anonymous and
were assigned an alphanumeric code). Two other blinded
investigators reviewed the results and recalculated the data
on the appearance of any difference.Analysis plan
The hip fractures during the follow up period were taken
as the endpoint event. At first, all fractures were col-
lected by TQ (structured interview), but were only
included in the analysis if these fractures were verified
against patients records. The characteristics of the popu-
lation were described according to descriptive univariate
analysis. We used the Chi-square test to evaluate the
association between qualitative variables. The Student’s
t-test or, if necessary, its non parametric equivalent, the
Mann–Whitney U test, was implemented to evaluate the
differences in the distribution of a quantitative variable
according to the categories defined by a binary exposure.
To assess the differences in the distribution of a quantita-
tive variable according to the categories defined by a
categorical variable with more than two categories,
ANOVA analysis of variance or its corresponding non
parametric test (Kruskal-Wallis) were used. The relative
risk (RR) was calculated by quotient between prevalence of
each risk factor in fractured women and in non-fractured.
To know the discriminating ability of the FRAX tool
we used AUC-ROC and the Hosmer-Lemeshow
goodness-of-fit test. The overall predictive capacity ratio
was calculated by comparison of observed fractures
(ObsFx) in the cohort and period and the expected
fractures (ExpFx) by the FRAX tool [sum of individual
probability of fracture from all women included/100].
The proportion of fractures expected is calculated by
the sum of an individual probability of fracture from all
women included/100. Model calibration is done by
multiplying the FRAX result by the ratio ObsFx/ExpFx.
All the statistical tests were undertaken with a confi-
dence interval of 95% and with the use of the 17th
version of the SPSS statistical package.
This work follows the guidelines of the STROBE initiative
for epidemiological studies [http://www.strobe-statement.
org/index.php?id=strobe-publications].
Ethics
Procedures for human subject protection and the
original protocol [35] were approved by the Clinical
Research Ethics Committee of the Vall d'Hebron University
Hospital, Barcelona, Spain and by the Ethical Committee
of the Institut Universitari d’Investigació en Atenció
Primària (IDIAP) Jordi Gol. Barcelona. Spain. Informed
consent was obtained before beginning the interviews of all
the patients.
Results
Among the person completing 10 years since their inclu-
sion in the cohort, 1,308 could be contacted for this
study (Figure 1). About 69 (5.3%) patients died (43.4%).
Thirty nine have been detected by searching the










484 no contact (23.3%)
59 refused participation(4.5%)
329 Treatment (29.4%)
60 men (5.1%) 
Figure 1 Flow chart study. Participant selection.
Table 1 Risk factors among participants/non participants
in the current study of FRIDEX cohort
Participants Non Participants p-value
(n= 1180) (n= 895)
Age years, mean (SD) 56.8 (8.0) 57.8 (8.5) <0.001
Weight in Kg., mean (SD) 66.6 (11.5) 65.9 (11.1) ns
Height in cm., mean (SD) 155.2 (5.9) 155.6 (6.0) ns
BMI in Kg/cm2 , mean SD) 27.7 (4.7) 27.9 (4.2) ns
Smoker, n (%) 132 (11.2%) 103 (11.5%) ns
Alcohol Risk, n (%) 6 (0.5%) 5 (0.5%) ns
Previous Fracture, n (%) 269 (22.8%) 245 (27.4%) ns
Parental osteoporosis or
fractures, n (%)
185 (15.7%) 138 (15.4%) ns
Glucocorticoids, n (%) 44 (3.7%) 53 (5.9%) 0.024
Rheumatoid Arthritis, n (%) 12 (1.0%) 11 (1.2%) ns
Calcium/Vit. D
Supplements, n (%)




329 (27.9%) 277 (30.9%) ns
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reported only 2 cases of fracture between baseline and
the date of death. A total of 770 women fulfilled the
inclusion criteria and provided informed consent to
participate.
During the 10 years of study 65 women presented a
total of 82 major osteoporotic fractures which could be
contrasted: 17 women with 18 hip fractures, 10 with 18
proximal humeral fractures, 25 with 30 forearm fractures,
and 14 with 16 vertebral fractures. All the fractures were
caused by low intensity impact according to the classical
definition of fragility fracture [26].
Table 1 shows the baseline characteristics of the parti-
cipants and those selected but did not participate in the
study. No significant differences were observed between
these two groups except that the participants ware one
year younger on average (56.8 vs. 57.8 years) and the
participants were taking glucocorticoids (3.7 vs. 5.9%).
Table 2 describes the main characteristics of the 770
participating women as well as the results of the vari-
ables or risk factors included in the FRAX tool and the
results of the baseline DXA expressed as the result
stratified according to the WHO classification. It also
includes the variable of falls in the previous year which
was assessed at the end of the study. The CRFs showing
significant differences between women with fractures
and those without fractures are: age, previous fractures,
having rheumatoid arthritis and having a diagnosis of
osteoporosis on DXA. The relative risks (RR) of the
different CRFs are shown separately for major fracture
and hip fracture in Tables 2 and 3.
The values of the different AUC-ROC for major and
hip fracture calculated in the cohort of Spanish womenare shown in Table 4. That is, of BMD by DXA with the
T-score of the femoral neck (FN) and with the T-score of
spine L1-L4 and the FRAX tool in three ways: without
BMD, with the FN T-score and with spine L1-L4 T-score.
The best result was for FRAX tool for hip fracture without
the T-score (0.888). In all cases the results presented signifi-
cant differences with the reference (0.50) except for BMD
with spine L1-L4 T-score (p=0.067). Figures 2 and 3 are
graphs of the AUC-ROC of the FRAX tool for major frac-
ture and hip fracture. A determination of the AUC-ROC
Table 2 Baseline risk factors and falls in previous year for major fracture
65 Women with fracture 705 Women without fracture P- value CI 95% RR CI 95% RR
Age (SD) 61.2 (9.7) 56.4 (7.7) <0.001 2.4-7.3 2.62 (*) (1.63 – 4.21)
Weight (SD) 67.4 (11.5) 66.6 (11.4) 0.559 ns - -
Height (SD) 155.3 (6.1) 155.1 (5.8) 0.805 ns - -
BMI (SD) 28.0 (4.4) 27.7 (4.7) 0.653 ns 1.19 (**) (0.31 – 4.53)
Previous Fracture (%) 43.1 18.6 <0.001 12.1-36.9 2.91 (1.84 – 4.60)
Parental Hip Fracture (%) 15.4 15.6 0.963 ns 0.98 (0.52 – 1.88)
Smoker (%) 9.2 11.3 0.604 ns 0.81 (0.36 – 1.82)
Alcohol Risk (%) 1.5 1 0.508 ns 1.49 (0.23 – 9.45)
Glucocorticoids (%) 7.7 2.8 0.052 ns 1.15 (0.94 – 1.40)
Rheumatoid Arthritis (%) 4.6 0.7 0.024 1.2-9.0 4.61 (1.83 – 11.63)
Falls in previous year (%) 32.3 22.3 0.066 ns 1.59 (0.97 – 2.60)
Osteoporosis (baseline DXA) (%) 50.8 25.8 <0.001 12.4-37.6 4.96 (‡) (1.98 – 12.43)
Osteopenia (baseline DXA) (%) 41.5 50.9 0.147 ns 2.36 (Φ) (0.93 – 6.03)
Normal (baseline DXA) (%) 7.7 23.3 0.004 8.4-22.8 - -
RR: Relative Risk.
(*) < 65 vs. ≥ 65 years.
(**) < 20 vs. ≥ 20.
(‡) Osteoporosis vs. normal.
(Φ) Osteopenia vs. normal.
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0.752 (CI 95%; 0.643-0.861) for the FRAX tool without
BMD, 0.815 (CI 95%; 0.725-0.905) with the FN T-score and
0.710 (CI 95%; 0.575-0.844) with L1-L4 T-score, without
significant differences among them (p=0.157) (graph not
shown). We compare AUC of the ROC curve of FRAX tool
for major and hip fracture with a simple model including
only age. The AUC in a model that includes only age wasTable 3 Baseline risk factors and falls previous year for hip fr
17 Women with fracture 753 Wome
Age (SD) 69.4 (7.1)
Weight (SD) 64.8 (8.1) 6
Height (SD) 153.1 (7.3) 1
BMI (SD) 27.7 (3.0)
Previous Fracture (%) 47.1
Parental Hip Fracture (%) 17.6
Smoker (%) 0.0
Alcohol Risk (%) 0.0
Glucocorticoids (%) 11.8
Rheumatoid Arthritis (%) 11.8
Falls in previous year (%) 35.3
Osteoporosis (baseline DXA) (%) 58.8
Osteopenia (baseline DXA) (%) 35.3
Normal (baseline DXA) (%) 5.9
RR: Relative Risk, ns: no statistical significance.
(*) < 65 vs. ≥ 65 years.
(**) < 20 vs. ≥ 20.
(‡) Osteoporosis vs. normal.
(Φ) Osteopenia vs. normal.0.668 for major fracture and 0.882 for hip fracture with no
significant differences with the results of FRAX tool
(p=0.565 and p=0.976 respectively).
Around 27 major fractures and 6 hip fractures were
expected with the FRAX tool without BMD, while
around 30 major fractures and 7 hip fractures were
expected with the inclusion of the T-score of the femoral
neck in the FRAX tool (Table 5).acture
n without fracture P- value CI 95% RR CI 95% RR
56.5 (7.8) <0.001 9.2-16.7 11.49 (*) (4.12 – 32.08)
6.7 (11.5) 0.498 ns - -
55.2 (5.8) 0.139 ns - -
27.7 (4.7) 0.945 ns 1.02 (**) (0.06 – 16.43)
20.1 0.012 3.1- 50.9 3.42 (1.34 – 8.71)
15.5 0.738 ns 1.16 (0.34 – 3.98)
11.4 0.242 ns 0.225 (0.01 – 3.71)
1.1 1.000 ns 2.42 (0.16 – 37.26)
3.1 0.102 ns 3.97 (0.96 – 16.45)
0.8 0.012 4.3-26.3 12.7 (3.46 - 46.63)
22.8 0.246 ns 1.81 (0.68 – 4.84)
27.2 0.004 8.0-55.2 7.86 (‡) (1.02 – 60.80)
50.5 0.215 ns 2.63 (Φ) (0.32 – 21.65)
22.3 0.106 ns - -
Table 4 Area Under Curve (AUC) of Receiver Operating Characteristics (ROC)
AUC ROC CI 95% p - value
AUC ROC 10-year prediction of MAJOR FRACTURE BMD with FN T-score 0.661 (0.583-0.739) p<0.001
BMD with L1-L4 T-score 0.638 (0.565-0.711) p<0.001
FRAXW tool without BMD 0.693 (0.622-0.763) p<0.001
FRAXW tool with FN T-score 0.716 (0.646-0.786) p<0.001
FRAXW tool with spine L1-L4 T-score 0.712 (0.644-0.780) p<0.001
AUC ROC 10-year prediction of HIP FRACTURE BMD with FN T-score 0.779 (0.631-0.929) p<0.001
BMD with L1-L4 T-score 0.630 (0.487-0.773) (ns)
FRAXW tool without BMD 0.888 (0.824-0.952) p<0.001
FRAXW tool with FN T-score 0.849 (0.737-0.962) p<0.001
FRAXW tool with spine L1-L4 T-score 0.767 (0.658-0.876) p<0.001
AUC ROC: Area Under Curve of Receiver Operating Characteristics; BMD: Bone Mineral Density; FN: Femoral Neck; L1-L4: Lumbar Spine; CI: Confidence Interval; ns:
Not significant.
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major fracture and 2.8 (CI 95%; 1.7 - 4.6) for hip fracture
(Table 5) with the FRAX tool without BMD and 2.2 (CI
95%; 1.7 - 2.8) and 2.3 (CI 95%; 1.4 - 3.8), respectively
with femoral neck T-score. Expressed in percentages, the
FRAX tool without BMD predicts 41.1% of the cases of
women with major fracture in 10 years and 46% on add-
ing the algorithm of the T-score of the femoral neck,
with these values being 35.5% and 42.8% for hip frac-
tures, respectively.
With respect to the analysis of the sample of the FRI-
DEX cohort we performed a goodness-of-fit test which
stratifies the results in quintiles of risk associated with
quintiles of results of fracture.FRAX without BMD FRAX wit
AUC: Area under curve.  
BMD: Body Mass Density.  
FN: Femoral neck 
Figure 2 AUC ROC of FRAX tool for major fracture in FRIDEX cohort.Figure 4 shows the Hosmer-Lemeshow test for major
fracture, with the cases of the sample distributed into
quintiles and the line of regression for the results of the
FRAX tool without BMD and with the FN T-score. The
lower part of the figure represents the same results after
calibration (simulation) by the number of times that the
ObsFx is greater than the ExpFx (Table 5). Figure 5
shows the results for hip fracture in the same way.
Discussion
According to the comparative analysis of the baseline
characteristics between the participants and the non par-
ticipants for any reason we found that the non partici-
pants did not differ from the participants except in thath FN BMD FRAX with spine L1-L4 BMD 
FRAX without BMD FRAX with FN BMD FRAX with L1- L4 BMD
AUC: Area Under Curve. 
BMD: Body Mass Density. 
FN: Femoral Neck
Figure 3 AUC ROC of FRAX tool for hip fracture in FRIDEX cohort.
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glucocorticoids. Thus, the participants in the study did
not present worst conditions of the cohort.
Self-reported generally even structured interview have
a significant correlation with those in the medical rec-
ord. In any case always been found documented as
explained. In all cases of fracture the medical records of
the patients were reviewed and, when necessary, we
requested a medical report for its validation. All cases of
fracture that could not be verified or those arising from
a motor vehicle accident or major trauma were excluded
from analysis, fractures in the history of the subjects
under study. A potential limitation of self-reported
fractures is in vertebral fractures. In our study the total
self-reported fractures were 16% higher than they were
registered and so were excluded from the final analysis.
It can be an advantage for risk predictions proposed by
FRAX.
The present study is centered on the discriminatory
and predictive capacity of the FRAX. Analysis of the
AUC-ROC was used to analyse the discriminatory
capacity of this tool. As shown in (Table 4) the results of
the FRAX without DXA values were greater than theTable 5 Ratio of Observed fractures/Expected fractures by FR
MAJOR FRACTURES
Obs Fx Exp Fx Ratio Fx Obs/Exp
FRAX without BMD 65 26.7 2.4
FRAX with FN T-score 65 29.9 2.2
MAJOR FRACTURES (hip, vertebra, humerus, wrist). Fx: Fracture.
ObsFx: Observed fractures; ExpFx: Expected fractures; CI: Confidence Interval;
BMD: Bone Mineral Density; FN: Femoral Neck.AUC-ROC of BMD with values of the T-score of the
femoral neck. Thus, these results demonstrate that the
FRAX without the determination of BMD presents a dis-
criminatory capacity not inferior to and even somewhat
better than the DXA, according to the AUC-ROC.
Analysis of the BMD with the DXA technique for the
axial skeleton has traditionally been considered as the
best predictive test known to determine fragility fractures
[9,26,36] with the strategy of intervention for their
prevention in medical practice having been based on this
test in Spain [35] and in the remainder of the inter-
national scientific community until the appearance of the
importance of other risk factors for fracture [27-33].
On analysing the role of the determination of BMD of
L1-L4 in the different tests, it was found that the dis-
criminatory capacity for major fracture using the AUC-
ROC was lower than that of the determination of BMD
with the T-score of the femoral neck, although statistical
significance was maintained (Table 4). This inferiority
was maintained for hip fracture but with no significant
differences since the confidence interval integrates the
value 0.50 which is the value of statistical significance
for this test. Part of the debate on the possibleAX tool
HIP FRACTURES
CI 95% Obs Fx Exp Fx Ratio Fx Obs/Exp CI 95%
(1.9 - 3.1) 17 6.0 2.8 (1.7- 4.6)
(1.7 - 2.8) 17 7.3 2.3 (1.4 - 3.8)
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of the BMD values of the lumbar spine in its algorithm.
This criticism is based on the traditional consideration
that the BMD of each area presents the best predictive
capacity for fractures in the same area, especially for the
vertebrae and the hip [36] and, thus, it has been argued
that the prediction of vertebral fractures could be
improved. The discriminatory capacity measured with
the AUC-ROC worsened with the incorporation of the
L1-L4 T-score in the algorithm of the FRAX for major
or hip fractures (Table 4). This result is congruent, but
on introducing the L1-L4 T-score value in the FRAX (as a
simulation) to analyse what would happen with vertebral
fracture, the result of the AUC-ROC for vertebral fracture
worsened slightly with respect to that obtained with the
FN T-score, although without significant differences.
Thus, on introducing the values of the L1-L4 T-score in
the FRAX in this study the result did not provide an
improvement in the discrimination of vertebral fractures
measured with the AUC-ROC. Although it has describedCalibration
x 2.4
Original
FRAX® tool for Major Fracture
without BMD
BMD: Body Mass Density. 
FN: Femoral Neck
Figure 4 Hosmer-Lemeshow test. FRAX tool for Major Fracture.that a correction can adapt the lumbar spine BMD and
improve the prediction for major and vertebral fractures
of FRAX [31] in our study by incorporating the lumbar
spine BMD did not improve the discriminative ability of
FRAX measured by AUC with femoral neck BMD neither
for major or vertebral fracture (data not showed).
The adjusted predictive capacity of the FRAX analysed
using the ObsFx/ExpFx ratio was far from the 1 value
which would be the desired result in the case of good
adjustment of the predictive capacity of the FRAX in
our country. In our cohort this ratio was of 2.4 for major
fracture and 2.8 for hip fracture. These values improved
minimally on the introduction of the T-score of the femoral
neck in the algorithm (2.2 and 2.3 respectively). Indeed, the
FRAX predicted the risk of major fracture in 41.1% of the
women and 35.5% for hip fracture without BMD, with
these values improving only slightly with 46% and 42.8%,
respectively on performing the BMD with DXA.
These data seem to coincide with the analysis recently
carried out in two cohorts of French women with aCalibration
x 2.2
Original
FRAX® tool for Major fracture 
with FN T-score
FRAX® tool for Hip Fracture
without BMD







BMD: Body Mass Density. 
FN: Femoral Neck
Figure 5 Hosmer-Lemeshow test. FRAX tool for Hip Fracture.
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overall sensitivity (48-50% for FRAX predictions) and better
than BMD alone [33,37]. In Spain our group previously
demonstrated that the FRAX has good capacity to detect
densitometric osteoporosis but also with imbalance in the
predictive capacity [38-40]. Nonetheless, a two recent
studies in Spain had shown similar results to ours for major
fractures with an ObsFx/ExpFx ratio of 3.1 (CI 95%: 2.8-
3.5) and 0.8 (CI 95%: 0.7-1.1) for hip fracture [41]. Although
the initial formation of the two cohorts followed very
similar schemes, the method of follow up in our study was
notably different. In the present study we only analysed
fragility fractures reported by the women, which could be
contrasted with electronic record or clinical reports. In the
second study the results of ratio ObsFx/ExpFx were 0.66
and 1.10 for major and hip fracture respectively [34]. The
most important methodological differences were that the
study was carry out for a three years period, the authors do
not included vertebral fractures [34].
The ROC curve has several problems. For analysis of
sensitivity and specificity we have not a gold standard ofFRAX for Spanish population. Moreover, ROC needs a
gold standard of illness (fracture) and we do not have
because of the electronic records are not completely
reliable and we needed to make a double check (self-
reported validate against records). On the other hand, the
area under the ROC curve is important, since it measures
the discrimination power of the model. Nevertheless, tests
of discrimination alone are not sufficient for model evalu-
ation, since they do not indicate whether calibration is
also good [34,35,42].
In our study, on application of the Hosmer-Lemeshow
test a good correlation was observed between the differ-
ent quintiles of risk in all the simulation (Figures 4, 5)
but with a line which groups the results of the regression
deviated from the reference toward the values observed.
This circumstance led us to carry out a calibration
multiplying each of the values resulting from the predic-
tion made by the FRAX by a constant based on the
ObsFx/ExpFx ratio for major fracture and for hip frac-
ture. As shown in the lower part (calibration) of Figures 4
and 5, on multiplication of the results of the FRAX by
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adjust perfectly to the diagonal of reference in the
Hosmer-Lemeshow test.
The FRAX tool can therefore be considered to present
with a poor discriminatory capacity for women to have
major osteoporotic fractures within 10 years, with this
capacity being good for hip fractures without the need of
determining the BMD, although this improves somewhat
with its determination. The FRAX tool shows a scarce
predictive capacity of the risk of fracture and predicts less
than 50% of those which occur. The reason for this under-
diagnosis may be because the Spanish cohort introduced
as the reference in the FRAX tool is not representative of
the current female population since these women present
significantly more fractures than those actually predicted
by the FRAX tool.
We have excluded from the analysis of the cohort of
women receiving active treatment for the bone at
baseline of the study because of the FRAX has so
defined, but we have not been excluded women who
received treatment during the 10-year period. This can
be a potential confounding factor, however exclude
women would mean removing the greatest potential for
fracture, but keep going who have received treatment
can be reduced the all risk of new fractures observed.
Other potential confounding factor can be the Calcium/
Vit D supplement intake because we have not excluded
at baseline or during the study period. There is import-
ant discussion in the literature about the role of these
supplements in reducing the risk of fracture, except in a
subgroup of patients taking bone active drugs for the
potential hypocalcaemia or in patients admitted to nursing
homes. These patients are not included in this study.
Moreover there is no significant difference between
Calcium/Vit D supplement intake between participants
and no participants.
New epidemiological studies are needed in our country
to compare these results on major and other fragility
fractures which, although not severe, also affect the
quality of life [43]. However, together with other authors
in our country [6,10,34,38-41] we believe that there are
sufficient data to promote the habit of investigating the
risk factors of fragility fracture among Spanish physi-
cians, especially in primary care, to determine the abso-
lute risk and be able to propose changes in lifestyle in
persons with a high risk as well as evaluate which
patients should be referred for determination of the
BMD by DXA [38]. In our opinion, the current state of
the FRAX needs some adjustments such as those
proposed in this study. Something similar to this need
for adaptation and adjustments happened in Spain with
the application of the first Framingham-type cardiovascular
risk scales which required adaptations such as the
REGICOR scale and others in our country [44-46].We know that the promoters of the FRAX are committed
to the adaptation of the tool to the different countries with
the publication of new studies such as what has been done
up to now. We also consider that with improvements this
may be a very useful tool especially in the first level of care
and this has been demonstrated by the important extension
in its use worldwide [28,35].
Conclusions
In summary, FRAX without BMD demonstrates a poor
discriminative capacity for major fractures and a good
discriminative capacity for hip fractures with the AUC
ROC for Spanish women but its predictive capacity does
not adjust well with the current algorithm leading to
underdiagnosis for major fracture and hip fractures. On
introducing the values of the L1-L4 T-score in the FRAX
tool, the result did not provide an improvement in the
discrimination of vertebral fractures measured with the
AUC-ROC. Simple models based on age or BMD alone
predicted 10-year risk of major and hip osteoporotic
fractures, as well as more complex FRAX models.
We advise our Spanish colleagues to use the FRAX
tool in clinical practice but weighing the resulting value
of each individual case of the FRAX without BMD by a
calibration value to obtain an absolute risk value of
major o hip fracture at 10 years. New studies may allow
a single value which is easier to remember in clinical
practice. The result obtained will be more adjusted to
the reality of the risk of fragility fracture in our country
according to the results found in the present and other
studies [34,38,41].
Study limitations and strengths
Our study has some strengths and limitations. We
assumed that women in the FRIDEX cohort could have
a higher risk of osteoporotic fractures than the general
population because it is a population that had previously
been selected to undergo a DXA scan for some reason.
However it is important to know the profile of women
who are selected to perform the DXA-scan by general
practitioners and other specialists as may higher but
close to the general population over 50 years. Fractures
occurring in the participants were followed by an ad-hoc
TQ taking into account the traditional low response
rates by post in previous epidemiological studies conducted
in Spanish population [36]. However, all fractures included
were verified against patient records.
Other potential confounders and biases are that we
excluded those who died during the follow-up, the collec-
tion of incident fractures is captured in retrospect, the
validation records was only for patients with fractures
and, as well, usually the electronic registers of fracture
tends to be less records than actually occur. To minimize
these potential biases we have verified all self-reported
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fulfill both (self-reported and recorded). Therefore, this
type of analysis tends to benefit the predicted fractures in
the ratio ObsFx/ExpFx.
We are aware that the authors of the FRAX tool apply
only the DXA value of the femoral neck because of the
absence of improvement in the prediction of major fracture
risk with the use of the lumbar spine T-score. This has been
one of the main criticisms related to the FRAX tool.
As strengths of the study, 4 investigators were involved
in the operating systems to verify the calculations of the
values of FRAX and all hip fractures included in the ana-
lysis were contrasted. The FRIDEX study is a prospective
population-based cohort study, being one of the first
studies to follow Spanish women over a 10-year period
to determine the incidence of fragility fractures.
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